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Peptide Linkers in Rats
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of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health
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Abstract
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The hepatic immunosuppressive activities of two novel dextran prodrugs of methylprednisolone
(MP) containing one (DMP1) or five (DMP5) amino acids as linkers were studied in rats. At
various times (0–2 weeks) after intravenous administration of single 5-mg/kg (MP equivalent)
doses of each prodrug or MP succinate (MPS), livers were isolated and immunologically
stimulated ex vivo with lipopolysaccharide. The concentrations of tumor necrosis factor (TNF)-α
in the outlet perfusate were then quantitated to assess immune response. Additionally, the
concentrations of DMP1, DMP5, and/or MP were measured in the liver. MPS, DMP5, or DMP1
injections caused a maximum of 48.9%, 63.5%, or 85.7% decrease in the TNF-α secretion into the
perfusate, with the time above the 50% inhibitory effect being <5, <24, or 120 h, respectively.
Additionally, the area under the effect-time curve for DMP1 was 11- or 4-fold higher than that
after the administration of MPS or DMP5, respectively. Relatively high concentrations of DMP1
were present in the liver even at the last sampling time of two weeks. These data suggest that a
single intravenous dose of DMP1 produces an intense and sustained immunosuppression in the
liver for a relatively long time, which may be useful in liver transplantation.

Keywords
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INTRODUCTION
The corticosteroid methylprednisolone (MP) has been used as an immunosuppressive agent
in liver transplantation for induction and early maintenance of the immunosuppression and
also for the treatment of acute rejection of the graft.1–5 For the induction purposes, MP is
usually administered intravenously immediately after the graft reperfusion at a high dose of
500–1000 mg.3,5 Additionally, MP at high intravenous bolus doses of 1000 mg per day,
administered over several days, is the first-line therapy for the treatment of acute liver graft
rejection.1,2,4 Despite a high degree of effectiveness, the large intravenous doses of MP are
associated with substantial toxicities, sometimes with fatal consequences.6–11 Therefore,
strategies to reduce the toxicity of large dose MP therapy are highly desirable.
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It has been proposed that selective immunosuppression in the graft might result in lower
toxicity that is related to excessive systemic immunosuppression, such as life-threatening
infections.12 Additionally, graft-selective immunosuppression would allow administration of
lower doses of the drug, further reducing the possibility of the overall side effects of the
drug not related to immunosuppression, such as cardiovascular13,14 and central nervous
system15–17 toxicities observed with the high dose MP. So far, different approaches have
been utilized to achieve graft-selective immunosuppression. These approaches mainly
include injection of the immunosuppressive drug directly into the vessels that supply the
blood to the transplanted organ18–20 or formulation approaches to target the graft after
systemic administration.21,22 Both of these approaches have been effective in various
experimental transplantation models.
We have used a macromolecular prodrug approach, based on neutral dextran carriers, for the
selective delivery of MP to the liver for the purpose of induction of immunosuppression and/
or treatment of acute rejection in liver transplantation. First, a conjugate linking MP to a 70
kDa dextran using a succinate linker was synthesized, and its pharmacokinetics23 and
pharmacodynamics24–26 were characterized in rats. After the systemic administration, the
conjugate selectively accumulated in the rat liver23 and was much more effective than the
parent drug in suppression of immune events in the liver.24,26 However, the release of MP
from the conjugate was slow and incomplete.24,25
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To control the in vivo rate of release of MP from the prodrug, second-generation dextran
conjugates were synthesized using peptides of different lengths as linkers.27 In vitro release
studies showed that the rate of release of MP from the prodrugs was positively related to the
length of the peptide linker when Gly and/or methyl Gly (mGly) were used as amino
acids.27 Further in vivo studies28 in rats using prodrugs containing one (DMP1) or five
(DMP5) amino acids as linkers showed a significant effect of the linker length on the
pharmacokinetics and tissue disposition of the prodrugs and the released MP. Whereas the
extent of accumulation of DMP1 in the liver, spleen, and kidneys was much higher than that
of DMP5, the rate of release of MP after DMP5 injection was faster than that of DMP1.
However, whether and how these pharmacokinetic differences affect the
immunosuppressive effects of the prodrug in the liver are not known at this time. Therefore,
the purpose of the current study was to determine the hepatic immunosuppressive effects of
DMP1 and DMP5, in comparison with that of an equivalent dose of the parent drug MP,
after the systemic administration of the prodrugs to rats. Based on the reported disposition
studies,28 our hypothesis was that whereas both prodrugs are more effective than the parent
drug, the DMP1 prodrug would produce the most intense and sustained immunosuppression
in the liver.
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MATERIALS AND METHODS
Chemicals
Dextran (average Mw: ~23500, degree of polydispersity: 2.3) was obtained from Dextran
Products, Ltd. (Scarborough, Ontario, Canada). Escherichia coli (Serotype 0111:B4)
lipopolysaccharide (LPS), sodium taurocholate, 6α-methylprednisolone succinate (MPS),
and internal standard (triamcinolone acetonide) were purchased from Sigma Chemical
Company (St. Louis, MO). Rat tumor necrosis factor (TNF)-α ELISA kit (ER3TNFA) was
obtained from Thermo Scientific (Rockford, IL). Kits for determination of transaminases
were purchased from Teco Diagnostics (Anaheim, CA). All other chemicals were of
analytical grade and obtained from commercial sources.
Dextran-methylprednisolone conjugates with methyl Gly (mGly) (DMP1) or mGly-GlyGly-Gly-Gly (DMP5), as the linkers between the polymer and MP, were synthesized and
J Pharm Sci. Author manuscript; available in PMC 2013 October 01.
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characterized as previously reported by us.27 The degrees of substitution (w/w) of the
conjugates were 10.8% and 7.6% for DMP1 and DMP5, respectively, with purities of >
95%.
Experimental Design
All procedures involving animals used in this study were consistent with the guidelines set
by the National Institutes of Health (NIH publication # 85-23 revised 1985) and approved by
our Institutional Animal Care and Use Committee.
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Adult, male Sprague-Dawley rats were obtained from Charles River laboratory
(Wilmington, MA) and housed in a 12-h light-dark cycle and temperature-controlled facility
with free access to rat chow and drinking water at all times. A total of 59 animals were used
for the entire study. Seventeen groups of animals with 3 animals per group were used to
study the time courses of the effects of MPS (at 5, 12, 24, and 48 h), DMP1 (at 5, 12, and 24
h and 2, 3, 5, 8, and 14 days), and DMP5 (at 5, 12, and 24 h and 2 and 5 days) on the LPSstimulated release of TNF-α. A single dose of MPS, DMP1, or DMP5, equivalent to 5 mg/
kg MP, was administered intravenously via the penile vein under isoflurane anesthesia. At
various times after each drug administration described above, rats were anesthetized, and
their livers were isolated and stimulated ex vivo with LPS using an isolated perfused rat
liver (IPRL) model. Additionally, a negative (n = 3) and a positive (n = 5) control group
were included in the study. The control groups did not receive any drug pretreatment before
the liver isolation. However, the livers of the positive control groups were stimulated ex
vivo with LPS, whereas the livers of the negative control group were not subjected to the
LPS stimulation.
Ex Vivo Perfusion and LPS Stimulation of the Isolated Livers
An IPRL model was used to test the hepatic immunosuppressive activity of the systemicallyadministered MPS, DMP1, or DMP5. This ex vivo model is based on the stimulation of
livers with LPS and the measurement of TNF-α released in the outlet perfusate, as described
in detail before.29 Briefly, after cannulation and isolation, the livers were transferred to a
temperature (37°C)-controlled chamber and perfused in a single-pass manner at 30 mL/min
(3–4 ml/g wet liver weight) for 120 min. The perfusate consisted of Krebs-Henseleit
bicarbonate buffer (pH 7.4), supplemented with 1.2 g/L glucose and 4.75 mg/L sodium
taurocholate, and was oxygenated with a 95:5 oxygen: carbon dioxide mixture.
The livers were mounted onto the IPRL system and allowed to stabilize for ~15 min. Except
for the negative control group, the livers were immunologically stimulated with 1 mL of a
300 μg/mL solution of LPS, which was infused at a rate of 50 μL/min for 20 min.29
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Liver viability was evaluated as described before30–32 via macroscopic examination,
relatively stable bile flow rates during the entire period of perfusion, low and stable inlet
pressure, low concentrations of aspartate (AST) and alanine (ALT) aminotransferases in the
perfusate at the beginning and end of the perfusion, and wet liver weights of <4% of total
body weight at the end of perfusion.
Sample Collection
Outlet perfusate samples (~1 mL) were collected at 0, 15, 30, 45, 60, 80, 100, and 120 min
for the measurement of TNF-α. Additional samples were collected at the start and end of
perfusion to determine the liver injury markers. Bile samples were collected in pre-weighed
tubes at 30 min intervals, and bile flow rates were determined gravimetrically. At the
completion of the perfusion, the livers were removed from the perfusion system, cleaned
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from the muscle and extraneous tissues, blotted dry, and weighed. The perfusate, bile, and
liver samples were stored at −80°C until further analysis.
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Sample Analysis
The concentrations of TNF-α in the outlet perfusate were quantified by ELISA according to
manufacturer’s directions. The assay, which uses a 50-μL sample, has a sensitivity of < 15
pg/mL with an inter- and intra-assay coefficient of variation of < 10%. The AST and ALT
levels in the perfusate were determined based on a colorimetric assay using commercial kits.
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The concentrations of MP, DMP1, and DMP5 in the liver were determined according to the
procedures reported by us before. Briefly, livers were homogenized in 2% acetic acid (1:3),
and the homogenate was used in the assay. For MP determination, a reverse phase HPLC
method was employed33 with a modified extraction procedure.28 Briefly, 600 μL of cold
acetonitrile containing 5 μg/mL triamcinolone acetonide (internal standard) was added to
240 μL of the liver homogenate, and the samples were vortex mixed for 30 sec and
centrifuged at 14000 rpm for 5 min. The supernatant was transferred to a centrifuge tube and
dried under a nitrogen stream. The dried residue was dissolved in 120 μL of methanol
followed by the addition of 120 μL of 10 mM sodium acetate buffer pH 4.5. A 100 μL
aliquot of the resultant solution was injected into the column. The samples were analyzed at
ambient temperature utilizing a 15 cm × 4.1 mm polystyrene-divinylbenzene copolymer (5
μm) column (PRP-1; Hamilton, Reno, Nevada), equipped with a 5-cm guard column packed
with pellicular C18 material. The mobile phase consisted of 100 mM acetate buffer (pH 5.7):
acetonitrile (77:23) pumped at 1.5 mL/min. The drug and internal standard were detected at
250 nm.
The concentrations of DMP1 and DMP5 in the liver homogenates were determined using a
size-exclusion assay reported by us28,34 with some modifications. To 100 μL of the liver
homogenate were added 50 μL of acetonitrile, 50 μL of methanol, and 20 μL of 70%
perchloric acid, and the samples were vortexed for 30 seconds and centrifuged at 14000 rpm
for 5 min. A 170 μL aliquot of the supernatant was then transferred to a new tube and 1 mL
of cold acetonitrile was added to precipitate the dextran conjugates. After vortex-mixing and
centrifugation, the supernatant was decanted, and the tube was dried for 3 min by inversion
on a paper towel. The residue was dissolved in 200 μL of mobile phase, and 100 μL was
injected into a 25 cm × 4.6 mm Nucleosil 100–7 OH column (Macherey-Nagel, Bethlehem,
PA). The analytes were eluted with a mobile phase of 10 mM KPO4 (pH 6.0): acetonitrile
(55:45) with a flow rate of 1 mL/min.
Data Analysis
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The area under the TNF-α concentration (outlet perfusate)-time curve (AUC) was calculated
using linear trapezoidal rule. The inhibitory effects of MP, DMP1, or DMP5 pretreatment on
the TNF-α secretion into the outlet perfusate were calculated as the percent inhibition of
TNF-α AUC using the following equation:24

(1)

where AUCPositive Control and AUCPretreatment refer to the TNF-α AUC in the positive
control group and that after the pretreatment of rats with MPS, DMP1 or DMP5,
respectively. The %inhibition of TNF-α was plotted against the time after the drug
administration, and the population mean and variance of the area under the effect
(%inhibition of TNF AUC)-time curve (AUEC) were estimated using sparse sampling
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model in Phoenix® WinNonlin® software (Pharsight, Sunnyvale, California). The mean and
variances of the AUC of MP, DMP1, or DMP5 in the liver during the sampling time
(AUClast) or from time zero to infinity (AUC∞) were also estimated by linear trapezoidal
rule for the sparse data using the same software. The concentration-time courses of DMP1
and DMP5 in the liver were fitted to the following biexponential equation:
(2)

where C1 and C2 are the concentration coefficients and k1 and k2 are the apparent first order
rate constants for the fast and slow decline phases, respectively. The population mean and
variance of the four parameters in the equation were estimated using the Phoenix® NLME®
software.
Statistical Analysis
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The effect of drug pretreatment on the TNF-α AUC in the outlet perfusate for different time
points was determined using one-way ANOVA followed by Dunnett’s post-hoc analysis,
comparing means for each time point after drug treatment with the positive control mean.
The effects of treatments on the average bile flow rates were determined by one-way
ANOVA, followed by Tukey’s Multiple Comparison test. The differences among MPS,
DMP1, and/or DMP5 in terms of their AUECs or liver AUCs, C1, C2, k1, and k2 were
analyzed using a two-sided Z-test after Bonferroni adjustment for the appropriate number of
comparisons, as described in detail before.23 All comparisons were performed at a
significance level (α) of 0.05 after Bonferroni adjustment, if applicable. The data are
presented as mean ± SD for parameters that could be estimated for individual animals (e.g.,
TNF-α AUC, bile flow rate, maximum effect, and maximum liver concentration) and as
mean ± SE for population parameters (e.g., AUEC and liver AUC and bi-exponential
parameters of prodrugs).

RESULTS
The bile flow rates for all the treatment groups were relatively high (Fig. 1) and stable
during the four collection intervals over the 2 h of perfusion (individual interval data not
shown). Neither LPS nor drug pretreatments significantly (p > 0.05) affected the average
bile flow rates (Fig. 1).
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The outlet perfusate concentration-time profiles of TNF-α in the negative and positive
control groups are shown in Fig. 2. Also depicted in the figure are the TNF-α profiles for
MPS at 5 h, DMP1 at 24 h, and DMP5 at 12 h after the drug treatments, representing the
peak effects of these treatments. For brevity, the TNF-α profiles at the other times after the
drug treatments are not shown. The data show very low concentrations of TNF-α in the
perfusate of the negative control livers. However, positive control livers show a delayed, but
steep increase in the TNF-α concentrations in the perfusate, starting at 30 min after the
stimulation with LPS (Fig. 2). All three drug treatments substantially reduced the LPSstimulated TNF-α release in the outlet perfusate, with the highest magnitude of the effect
seen with DMP1 (at 24 h), followed by DMP5 (at 12 h) and MPS (at 5 h) (Fig. 2). In fact,
the TNF-α profile at 24 h after the administration of DMP1 was almost indistinguishable
from the profile in the negative control group (Fig. 2).
The extent of suppression of TNF-α release after various pretreatments at each time point
may be quantified by calculating the AUC of TNF-α concentration-time curves, which are
presented in Table 1. The LPS stimulation of the livers without pretreatment (time zero in
Table 1) resulted in a significant increase in the TNF-α AUC, as compared with the AUC in
the negative control group, which was close to zero. Pretreatment with MPS showed a
J Pharm Sci. Author manuscript; available in PMC 2013 October 01.

Shaik et al.

Page 6

NIH-PA Author Manuscript

significant reduction (p < 0.05) in the TNF-α AUC at 5 h after the drug treatment. However,
the AUCs at the later time points after the MPS injections were not significantly different
from the AUC at time zero (positive control). In contrast to MPS, DMP1 injections resulted
in significant (p < 0.01) reductions in the TNF-α AUC lasting for up to 5 days after the drug
injection. On the other hand, the reductions in the TNF-α AUC after DMP5 injection,
although lasting longer than those after the MPS injection, were not significant beyond 12 h
following the conjugate injection (Table 1).

NIH-PA Author Manuscript

The effects of various drug pretreatments, expressed as % inhibition of TNF-α AUC, at
different times after the drug administration are presented in Fig. 3. Additionally, the
associated pharmacodynamic parameters are presented in Table 2. The maximum effect of
MPS treatment was 49% reduction in the TNF-α AUC, which occurred at the first sampling
time of 5 h. Thereafter, the effect decreased rapidly with less than 15% inhibitory effect
remaining at the last sampling point of 48 h (Fig. 3). Pretreatment with DMP5 resulted in a
maximum inhibitory effect of 64% observed at 12 h after the drug injection, which was not
significantly higher than the maximum effect after the MPS injection (Table 2). However,
the immunosuppressive effect of DMP5 lasted longer than that of MPS, falling below 15%
at 5 days after the injection (Fig. 3). Among the 3 drug pretreatments, DMP1 showed the
highest inhibitory effect (86%), which was observed at 24 h after the drug injection (Fig. 3
and Table 2). Additionally, the effect of DMP1 was much more sustained than that of either
MPS or DMP5, with the last sampling time of 14 days showing a 26% inhibitory effect (Fig.
3). In terms of the overall effect, the area under the effect (%inhibition of TNF AUC)-time
curve (AUEC) values, calculated for the duration of sampling, were 2.5 and 11 fold higher
for DMP5 and DMP1, respectively, when compared with the parent drug MPS (Table 2). In
addition, the time above 50% inhibition for DMP1 (120 h) was substantially longer than that
for the MPS and DMP5 pretreatments (Table 2).
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The liver concentration-time curves of DMP1 and DMP5 and the released active molecule,
MP, after a single 5-mg/kg dose (MP equivalent) are shown in Fig. 4. Additionally, the
associated non-compartmental pharmacokinetic parameters are listed in Table 3. Although
after the MPS injection the liver concentrations of MP were not detectable in any of the
samples, relatively high concentrations of DMP1 and DMP5 were quantifiable in all the
measured samples (Fig. 4). Additionally, the released MP was quantifiable for up to 12 and
48 h after the DMP5 and DMP1 injections, respectively (Fig. 4). For both DMP1 and
DMP5, the highest liver concentration was observed at the first sampling time of 5 h.
However, the maximum concentration for DMP1 (37.9 μg/g) was almost 8 times higher
than that for DMP5 (4.82 μg/g) (Table 3). The higher liver concentration of DMP1,
compared with DMP5, was reflected in 9 and 5 fold higher AUClast and AUC∞,
respectively, for this conjugate (Table 3). In agreement with the data for the prodrugs, the
Cmax and AUClast of the regenerated MP after DMP1 treatment were 3.6 and 17 fold higher
than those after the DMP5 treatment (Table 3).
The results of the biexponential fit of the liver concentration-time data for DMP1 and DMP5
are presented in Table 4. As expected from Fig. 4, the concentration coefficients (C1 and C2)
for DMP1 were significantly higher than the corresponding values for DMP5. As for the rate
constants, although the terminal rate constants (k2) were similar for both prodrugs, the rate
constant associated with the fast decline in the liver concentrations (k1) for DMP5 was 3.7
fold higher than that for DMP1 (Table 4).
The plots of % inhibition of TNF-α AUC versus DMP1 and DMP5 concentrations in the
liver are shown in Fig. 5. Both DMP1 and DMP5 showed indications of counter-clockwise
hysteresis loops, suggesting that the effect is delayed relative to the appearance of the
prodrug in the liver. The plots also suggest that at similar liver concentrations, DMP5 and
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DMP1 produce similar effects as the effect-concentration data points for DMP5 are almost
superimposable on the data points related to the lower liver concentrations of DMP1 (Fig.
5).

DISCUSSION
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In the current study, we compared the hepatic immunosuppressive activities of MP and its
two recently-developed novel prodrugs after their systemic administration. Although all the
pretreatments used here (MPS, DMP1, and DMP5) showed immunosuppressive activities in
the liver, the intensity and duration of the effect was formulation dependent. The rank order
for the intensity of the maximum effect and the duration of effect was DMP1 > DMP5 >
MPS (Figs. 2 and 3 and Table 2), which was in apparent agreement with the extent of the
exposure of the liver to the prodrugs and/or the active moiety (i.e., MP) (Fig. 4). After
administration of MPS, we could not detect MP in the liver samples, which were taken ≥ 5 h
after the drug injection. This is consistent with our previous report28 showing that the liver
concentrations of MP reach their maximum shortly after the administration of the parent
drug and are not detectable beyond 2 h after a single 5-mg/kg dose of the drug. In contrast to
the MPS injection, we were able to quantify MP regenerated from DMP5 and DMP1 for 12
and 48 h, respectively, following equivalent doses (Fig. 4). Overall, these data suggest that
DMP1 exhibits optimal pharmacokinetic and pharmacodynamic characteristics for situations
requiring intense and sustained immunosuppression in the liver.
The liver disposition data in Fig. 4 and Table 4 reveal some major differences between the
two conjugates in their hepatic disposition. First, the lower concentration coefficients (C1
and C2) for DMP5 indicate a lower extent of liver accumulation for this conjugate relative to
that for DMP1. Additionally, the observation that the concentrations of both DMP1 and
DMP5 in the liver decline in a biexponential manner is suggestive of the presence of two
processes contributing to the decline in the liver concentrations of the conjugates. Because
dextrans by themselves do not have a chromophore in their structure, the decline in the liver
concentrations of the conjugate is most likely due to the release of MP from the conjugate.
Therefore, the rate constants k1 and k2 are most likely representative of a fast and a slow
release process, respectively. The reasons for the two release processes (Table 4) are not
clear based on our current data. However, one may speculate that the conjugation of MP to
different hydroxyl groups of the glucose monomer may result in different types of
conjugates with different degrees of steric hindrance for access by peptidases. Nevertheless,
these data (Table 4) suggest that whereas the slower release process, represented by k2, is
similar for both conjugates, the fast release process, represented by k1, is ~4 fold higher for
DMP5, compared with DMP1.

NIH-PA Author Manuscript

Although the pharmacokinetics and pharmacodynamics of a first-generation dextran-MP
conjugate with a succinate linker (DMP-Succinate) have been investigated relatively
extensively, this study is the first to investigate the pharmacodynamics of the newlydeveloped dextran-peptide-MP conjugates. There are only two publications27,28 available
related to these novel conjugates. The first publication27 described the synthesis and in vitro
release characteristics of a series of dextran-MP conjugates with Gly peptide linkers of
different lengths. The in vitro release data using peptidases or rat liver lysosomal fractions
showed a linear positive relationship between the rate of MP release from the conjugate and
the length of the peptide linker. Our in vivo data showing ~4 fold higher k1 for DMP5,
compared with DMP1 (Table 4), appear to be in agreement with these in vitro data.27
The second publication dealing with the novel DMP conjugates investigated the relatively
short-term (12–24 h) plasma and tissue pharmacokinetics of DMP1 and DMP5.28 Whereas
the conjugates were not detectable in lungs, heart, and brain, relatively high concentrations
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of the conjugates were found in the liver, spleen, and kidney, suggesting selective
accumulation of the conjugates in the latter tissues. Similar to our current observation (Fig.
4), the liver concentrations of DMP1 were substantially higher than those of DMP5 in the
previous report.28 However, in contrast to our current data (Fig. 4), the conjugates showed
an apparent monoexponential decline in their liver concentration-time courses in the
published study. This apparent discrepancy is most likely due to the shorter sampling times
(12 and 24 h for DMP5 and DMP1, respectively) in the published study.28 In fact, if one
considers only the first 12 (DMP5) or 24 (DMP1) h data in the current study (Figure 4), the
multiexponential nature of the data would disappear. The longer sampling times, resulting in
the detection of a second slower phase in the current study, is also responsible for the higher
liver AUC values reported in Table 3, compared with the data in the previous study.28
Overall, the liver disposition data reported here (Fig. 4 and Table 4) agree with and extend
our previous knowledge28 about the fate of these conjugates in the liver.
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Although this is the first report on the pharmacologic activity of the novel conjugates of MP
with amino acid/peptide linkers, the pharmacodynamics of a different dextran prodrug of
MP with a succinate linker (DMP-Succinate) have already been reported.24 The data
presented in this manuscript suggest that not only is DMP1 superior to DMP5 (Fig. 3 and
Tables 1 and 2), it has also more suitable pharmacodynamic characteristics than the
conjugate with the succinate linker (DMP-Succinate). Whereas the peak effect time (24 h for
both) and the maximum inhibitory effect (86% for DMP1 and 80% for DMP-Succinate) are
similar for the same dose of the prodrugs, the duration of the effects of DMP1 is much
longer than that of DMP-Succinate. This conclusion is based on a significant inhibition of
TNF-α AUC by 2 days for DMP-Succinate,24 as compared with a 5-day inhibition for
DMP1 (Table 1). Additionally, the AUEC of DMP1 determined in the current study (638
%inhibition.day) is >four fold higher than that of DMP-Succinate (153 %inhibition.day).24
These data indicate that at equivalent MP doses, DMP1 produces a more sustained effect
than the first generation DMP-Succinate prodrug.
The significant differences between DMP1 and DMP-Succinate in terms of their length of
the effect could be attributed to the differences between the prodrugs in terms of the extent
of their liver accumulation and/or rate of MP regeneration. However, our previous study24
showed that the concentrations of DMP-Succinate in the liver during the 72 h of
measurement were similar to or higher than those observed here for DMP1 (Fig. 4).
Therefore, the longer effect of DMP1, observed in the present study, compared with that of
DMP-Succinate, reported before, is most likely due to the differences between the prodrugs
in terms of release of MP.
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The effect-liver concentration plots for DMP1 and DMP5 suggest the presence of a counterclockwise hysteresis (Fig. 5). This is in agreement with our previous report for DMPSuccinate, which also showed a counter-clockwise hysteresis in its effect.24 Theoretically, a
counter-clockwise hysteresis for a prodrug may be due to a delay in the regeneration of the
active drug. However, the counter-clockwise hysteresis was also observed when the effects
was plotted against the regenerated MP after DMP-Succinate, administration.24 These
observations are in agreement with previous studies29,35 reporting a several-hour delay
between the injection of MP and inhibition of LPS-stimulated TNF-α release.
The exact mechanisms of the inhibitory effects of glucocorticoids on the LPS-stimulated
TNF-α release are not fully understood. It has been reported36,37 that glucocorticoids, such
as MP, act at several points in stimulated macrophages or monocytes to prevent the release
of TNF-α by inhibiting TNF-α gene transcription and/or translation. In vitro data has shown
that LPS stimulation transiently increases the expression of TNF-α gene.37 Although
glucocorticoids antagonize this enhanced expression, they do not affect the TNF-α gene
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expression in the absence of LPS stimulation. Additionally, the data in murine cells suggest
that the glucocorticoids inhibit the enhanced translation of TNF-α mRNA in stimulated
monocytes.38 Overall, the available data indicate that the inhibitory effects of MP on TNF-α
release are indirectly related to the liver concentrations of MP. Therefore, the apparent
counter-clockwise hysteresis observed in the DMP1 and DMP5 effects (Fig. 5) are due most
likely to the delay in the effects of MP and not the release of MP from the prodrugs. Indeed,
in agreement with our data, Waage35 reported that the maximum inhibitory effects of
dexamethasone on TNF-α release in rats occurred when dexamethasone was administered 5
h before the injection of LPS.
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In addition to the use of dextrans, other approaches have also been reported for targeted
delivery of MP39 or other corticosteroids40 to the liver or other organs of reticuloendothelial
system. For example, Mishina et al.39 developed a liposomal formulation of MP and showed
its superior immunosuppressive activities, over the parent drug, in a heart transplantation
model.41 However, the immunosuppressive activity of the formulation in the liver was not
reported. Additionally, Melgert et al.40 synthesized an albumin conjugate of dexamethasone,
which was selectively distributed into the non-parenchymal cells of the liver. However, the
overall accumulation of the conjugate in the liver was not substantially different from that
after the administration of the parent drug. Nevertheless, the substantial and sustained
accumulation and effects of DMP1 in the liver over a period of two weeks, observed in our
studies (Fig. 4), does not appear to be achievable with the previously reported delivery
strategies for corticosteroids.
A limitation of our study is that only one marker (TNF-α) was used as a measure of
pharmacological effects of MP. However, it is likely that MP affects other markers of
immune response, in addition to TNF-α, in liver transplant patients. For example,
corticosteroids inhibit T-cell-derived and antigen-presenting cell-derived expression of
interleukins (ILs) such as IL-1, IL-2, IL-3, and IL-6.42 However, our LPS model did not
result in measurable levels of IL-1β and IL-6 in the perfusate during the relatively short
period of the perfusion (120 min).24 Therefore, we were not able to investigate the effects of
MP on these cytokines in this study. Another limitation of our IPRL model is that the
isolated organ is perfused with a buffer, instead of blood. Therefore, it lacks blood cells such
as leukocytes, which contribute to the inflammatory processes in vivo. Nevertheless,
previous studies24,26 from our laboratory have shown that despite these limitations, the
model successfully predicts the in vivo immunosuppressive effects of corticosteroids after
liver transplantation in rats.
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Finally, it should be noted that our IPRL model determines the immunosuppressive effects
of the systemically-administered drugs only in the liver, without any information about the
immunosuppressive activity in other organs. Because we have previously shown that the
prodrugs selectively accumulate in the liver, spleen, and kidneys,28 with no accumulation in
most other organs,28 one may expect an increased local immunosuppression in the spleen
and kidneys, in addition to the liver, after systemic administration of the prodrug.

CONCLUSION
In conclusion, the studies presented here show that novel dextran prodrugs of MP with
linkers consisting of one (DMP1) or five (DMP5) amino acids exhibit more substantial and
sustained immunosuppressive activity in the liver than an equivalent dose of the parent drug.
Further, the magnitude and duration of the effect of DMP1 were substantially higher than
those of DMP5. A single 5-mg/kg dose of DMP1 persisted in the liver for more than 14
days, gradually releasing the active drug and producing a sustained immunosuppressive
activity in the liver. These data suggest that DMP1 may be a suitable candidate for clinical
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situations, such as liver transplantation, requiring high concentrations of MP locally in the
liver over a sustained period of time. Further pharmacodynamic studies are required to
determine the effects of the prodrug in a liver transplantation model.
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Figure 1.
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Average bile flow rates of livers during 2 h of ex vivo perfusion. The livers were isolated at
different times following pretreatment of animals with a single 5-mg/kg (MP equivalent)
dose of MPS, DMP1, or DMP5. The columns and bars represent the mean and SD values,
respectively (n = 3–5/group).
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Figure 2.

The concentration-time profiles of TNF-α in the outlet perfusate of livers isolated from
untreated animals (negative and positive controls) and the animals pretreated with a single 5mg/kg (MP equivalent) dose of MPS, DMP5, or DMP1 at 5, 12, or 24 h before the liver
isolation, respectively. Except for the negative control group, all the livers were stimulated
with 300 μg of LPS during the first 20 min of ex vivo perfusion. The symbols and bars
represent the mean and SD values, respectively (n = 3–5/group).

NIH-PA Author Manuscript
J Pharm Sci. Author manuscript; available in PMC 2013 October 01.

Shaik et al.

Page 15

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 3.

The time course of the inhibitory effects of a single 5-mg/kg (MP equivalent) dose of MPS,
DMP1, or DMP5 on the release of TNF-α into the outlet perfusate of livers stimulated with
300 μg of LPS during the first 20 min of ex vivo perfusion. The symbols and bars represent
the mean and SD values, respectively (n = 3–5/group).
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Figure 4.
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The hepatic concentration time courses of DMP1, DMP5, and MP regenerated from the
prodrugs following a single 5-mg/kg (MP equivalent) dose of the prodrugs. The symbols
and bars represent the mean and SD values, respectively (n = 3/group), and the lines for
DMP1 and DMP5 are based on the biexponential model with parameters in Table 4.
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Figure 5.

The effect-hepatic concentration time profiles following a single 5-mg/kg (MP equivalent)
dose of DMP1 or DMP5. The symbols and arrows represent the mean and the progression of
sampling time, respectively ((n = 3–5/group).
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The Pharmacodynamic Parameters of Single 5-mg/kg (MP Equivalent) Doses of MPS, DMP1, or DMP5
Administered Intravenously to Rats
Parameter

MPS

DMP5

DMP1

5

12

24

Maximum Inhibitory Effect (%)

48.9 ± 11.3a

63.5 ± 2.0b

85.7 ± 2.9a,b

Time above 50% Inhibition (h)

<5

< 24

120

59.2 ± 5.3a,c

149 ± 26b,c

638 ± 72a,b

Peak Time (h)

AUEClast (%Inhibition.Day)

The effect was measured as the %inhibition of TNF-α AUC in the outlet perfusate of the livers stimulated ex vivo with LPS.

a

Significant difference between MPS and DMP1 based on Z test.

b

Significant difference between DMP1 and DMP5 based on Z test.

c

Significant difference between MPS and DMP5 based on Z test.
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The Pharmacokinetic Parameters of Single 5-mg/kg (MP Equivalent) Doses of DMP1 and DMP5 After
Intravenous Administration to Rats
Parameter

DMP5 Injection

DMP1 Injection

DMP5

Released MP

DMP1

Released MP

5

5

5

5

4.82 ± 2.29a

0.200 ± 0.184b

37.9 ± 7.2a

0.728 ± 0.234b

AUClast (μg.h/g)

141± 9a

1.38 ± 0.64b

1250 ± 64a

23.9 ± 3.1b

AUC∞ (μg.h/g)

306

NDc

1490

NDc

Peak Time (h)
Maximum Conc. (μg/g)

a

Significant difference between DMP1 and DMP5 based on Z test.

b

Significant difference between MP generated from DMP1 and MP generated from DMP5 based on Z test.

c

ND, Not determined.
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The Biexponential Parameters of Liver DMP1 or DMP5 Concentration-Time Courses after Single Intravenous
Doses of 5-mg/kg (MP Equivalent) of Each Prodruga
Parameter

DMP5

DMP1

C1 (μg/g)

3.71 ± 2.50b

36.4 ± 8.9b

C2 (μg/g)

1.20 ± 0.09b

3.59 ± 0.38b

k1 (Day−1)

7.13 ± 0.89b

1.95 ± 0.00b

k2 (Day−1)

0.115 ± 0.010

0.107 ± 0.018

a

The error values are related to between subject variability.

b

Significant difference between DMP1 and DMP5 based on Z test.
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